Dianthus Therapeutics Q3 net loss $25.2M; cash $342.6M; Phase 3 CIDP trial planned by YE 2024

Dianthus Therapeutics, Inc. /DE/

2024-Q3 EPS reported -$1.73 revenue$4,909,000

Net loss $25.2M ($0.74/sh) vs $14.8M ($3.78/sh) in Q3 2023; R&D expense rose to $25.5M from $8.0M.
Cash, equivalents and investments $342.6M as of Sept 30, 2024; projected runway into 2H 2027.
Initiation of pivotal Phase 3 CIDP trial (single, two-part, randomized withdrawal) expected by year-end 2024.
Phase 2 MaGic gMG trial on track for top-line data 2H 2025; Phase 2 MoMeNtum MMN trial for 2H 2026.
Steven Romano, M.D., appointed to board effective Sept 16, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.